Peptide Modifications & Engineering
Chemical and structural tweaks that transform natural peptides into more stable, potent, and useful molecules.
Why Modify Peptides?
Natural peptides often suffer from poor stability (protease degradation), short half-life, low oral bioavailability, and rapid clearance. Strategic modifications address these while preserving or enhancing biological activity.
Common Modification Strategies
N- and C-Terminal Modifications
- Acetylation (N-terminal) — Blocks exopeptidases, improves stability.
- Amidation (C-terminal) — Mimics natural amidated peptides, increases stability and activity.
- Other caps — Formyl, pyroglutamyl, or lipid groups for membrane targeting.
Side-Chain Modifications
- D-amino acids — Resist proteolytic enzymes; used in many therapeutics.
- Non-natural amino acids — Introduce new properties (e.g., fluorinated residues for NMR or PET imaging).
- Phosphorylation or glycosylation mimics — For signaling studies or stability.
Cyclization
Connecting N- and C-termini or side chains creates rigid structures resistant to exopeptidases.
- Head-to-tail cyclization
- Disulfide bridges (e.g., in defensins, oxytocin)
- Lactam or thioether bridges
PEGylation and Conjugation
- PEGylation — Attaching polyethylene glycol chains increases hydrodynamic size, reduces renal clearance, and can shield from immune recognition.
- Lipidation — Fatty acid attachment promotes albumin binding and extends half-life (e.g., semaglutide).
- Drug conjugates — Linkers attach cytotoxic payloads (peptide-drug conjugates for targeted cancer therapy).
Stapled & Constrained Peptides
Hydrocarbon "staples" or other bridges lock peptides into bioactive conformations (often α-helical), improving binding affinity, cell permeability, and protease resistance. Many stapled peptides are in clinical development for intracellular targets once considered "undruggable."
Impact on Drug Development
Modifications have enabled oral peptide drugs (e.g., oral semaglutide using permeation enhancers), longer-acting injectables, and tissue-targeted delivery. They also allow fine-tuning of receptor selectivity and duration of action.
Challenges
- Balancing activity vs. stability
- Manufacturing complexity and cost
- Immunogenicity of modified sequences
- Regulatory pathways for novel modifications